These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1930638)

  • 1. Evidence in support of the plasma membrane as the target for transferrin-adriamycin conjugates in K562 cells.
    Barabas K; Sizensky JA; Faulk WP
    Am J Reprod Immunol; 1991 Apr; 25(3):120-3. PubMed ID: 1930638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin-adriamycin conjugates which inhibit tumor cell proliferation without interaction with DNA inhibit plasma membrane oxidoreductase and proton release in K562 cells.
    Faulk WP; Barabas K; Sun IL; Crane FL
    Biochem Int; 1991 Dec; 25(5):815-22. PubMed ID: 1666508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells.
    Berczi A; Barabas K; Sizensky JA; Faulk WP
    Arch Biochem Biophys; 1993 Jan; 300(1):356-63. PubMed ID: 8424669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells.
    Fritzer M; Barabas K; Szüts V; Berczi A; Szekeres T; Faulk WP; Goldenberg H
    Int J Cancer; 1992 Oct; 52(4):619-23. PubMed ID: 1399145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in cancer research: drug targeting without the use of monoclonal antibodies.
    Faulk WP; Harats H; McIntyre JA; Berczi A; Sun IL; Crane FL
    Am J Reprod Immunol; 1989; 21(3-4):151-4. PubMed ID: 2640441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the anti-cancer activity of transferrin-adriamycin conjugates.
    Sizensky JA; Barabas K; Faulk WP
    Am J Reprod Immunol; 1992; 27(3-4):163-6. PubMed ID: 1418408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transferrin conjugates in the anticancer therapy].
    Lubgan D; Marczak A; Distel L; Jóźwiak Z
    Postepy Biochem; 2006; 52(1):72-9. PubMed ID: 16869304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates.
    Sun IL; Sun EE; Crane FL; Morré DJ; Faulk WP
    Biochim Biophys Acta; 1992 Mar; 1105(1):84-8. PubMed ID: 1567898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA.
    Barabas K; Sizensky JA; Faulk WP
    J Biol Chem; 1992 May; 267(13):9437-42. PubMed ID: 1577771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients.
    Faulk WP; Taylor CG; Yeh CJ; McIntyre JA
    Mol Biother; 1990 Mar; 2(1):57-60. PubMed ID: 2334538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy.
    Kratz F; Beyer U; Roth T; Tarasova N; Collery P; Lechenault F; Cazabat A; Schumacher P; Unger C; Falken U
    J Pharm Sci; 1998 Mar; 87(3):338-46. PubMed ID: 9523988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis.
    Bérczi A; Ruthner M; Szüts V; Fritzer M; Schweinzer E; Goldenberg H
    Eur J Biochem; 1993 Apr; 213(1):427-36. PubMed ID: 8477715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diferric transferrin reductase in the plasma membrane is inhibited by adriamycin.
    Sun IL; Navas P; Crane FL; Morré DJ; Löw H
    Biochem Int; 1987 Jan; 14(1):119-27. PubMed ID: 3566771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?
    Morré DJ; Kim C; Paulik M; Morré DM; Faulk WP
    J Bioenerg Biomembr; 1997 Jun; 29(3):269-80. PubMed ID: 9298712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
    Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
    Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
    Hatano T; Ohkawa K; Matsuda M
    Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing of human tumor cells in culture with adriamycin conjugates of human transferrin.
    Yeh CJ; Faulk WP
    Clin Immunol Immunopathol; 1984 Jul; 32(1):1-11. PubMed ID: 6329566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constructing transferrin receptor targeted drug delivery system by using doxorubicin hydrochloride and vanadocene dichloride.
    Zhang Y; Xiang J; Liu Y; Zhang X; Tang Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5982-6. PubMed ID: 21862329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to adriamycin of transplasma membrane electron transport in adriamycin-resistant and nonresistant HL-60 cells.
    Morré DJ; Morré DM; Wu LY
    J Bioenerg Biomembr; 1994 Feb; 26(1):137-42. PubMed ID: 8027019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of a doxorubicin-transferrin conjugate with isolated transferrin receptors.
    Ruthner M; Berczi A; Goldenberg H
    Life Sci; 1994; 54(1):35-40. PubMed ID: 8255167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.